Sino Biopharmaceutical enrolls first patient in phase 1 trial for TRD208

Sino Biopharmaceutical Limited has completed the enrollment of the first patient in the phase 1 clinical trial for TRD208, a National Class 1 innovative drug. TRD208 is a first-in-class, non-opioid, multi-target, multi-modal analgesic, independently developed by the group, and is poised to become a significant innovative drug in acute pain management.

TRD208’s unique mechanism targets multiple pain transmission pathways in the central nervous system, including NaV1.7 and NaV1.8, and exhibits anti-inflammatory and analgesic effects similar to NSAIDs. Pre-clinical data indicates rapid onset, potent analgesic effects, and prolonged action for postoperative pain, with the potential to replace current mainstream combination therapies.

The company is committed to accelerating research into innovative analgesic therapies. This novel agent aims to simplify treatment, improve patient compliance, and eliminate risks associated with opioid-related addiction and dependence.